Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
Journal of Personalized Medicine · 21.09.2023 · 13 (9) · 1423
DOI: 10.3390/jpm13091423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 21.09.2023. Verfasst von Lyudmila A Levchuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, Russia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Russian Science Foundation.
Abstract (Originalsprache)
Nowadays, nervous tissue damage proteins in serum are considered promising drug targets and biomarkers of Mood Disorders. In a cross-sectional naturalistic study, the S100B, MBP and GFAP levels in the blood serum were compared between two diagnostic groups (patients with Depressive Episode (DE, n = 28) and patients with Recurrent Depressive Disorder (RDD, n = 21)), and healthy controls (n = 25). The diagnostic value of serum markers was assessed by ROC analysis. In the DE group, we did not find changed levels of S100B, MBP and GFAP compared with controls. In the RDD group, we found decreased S100B level (p = 0.011) and increased MBP level (p = 0.015) in comparison to those in healthy controls. Provided ROC analysis indicates that MBP contributes to the development of a DE (AUC = 0.676; 95%Cl 0.525–0.826; p = 0.028), and S100B and MBP have a significant effect on the development of RDD (AUC = 0.732; 95%Cl 0.560–0.903; p = 0.013 and AUC = 0.712; 95%Cl 0.557–0.867; p = 0.015, correspondingly). The study of serum markers of nervous tissue damage in patients with a current DE indicates signs of disintegration of structural and functional relationships, dysfunction of gliotransmission, and impaired secretion of neurospecific proteins. Modified functions of astrocytes and oligodendrocytes are implicated in the pathophysiology of RDD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634014, Russia.
- Psychiatry, Addictology and Psychotherapy Department, Siberian State Medical University, Tomsk 634050, Russia.
ORCID-Profile: Lyudmila A Levchuk, Ekaterina V Mikhalitskaya, Elena V Epimakhova, German G Simutkin, Svetlana A Ivanova
Förderung
- The Russian Science Foundation
Zitieren
APA
Levchuk, L. A., Roschina, O. V., Mikhalitskaya, E. V., Epimakhova, E. V., Simutkin, G. G., Bokhan, N. A., & Ivanova, S. A. (2023). Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders. Journal of Personalized Medicine, 13(9), 1423. https://doi.org/10.3390/jpm13091423
Vancouver
Levchuk LA, Roschina OV, Mikhalitskaya EV, Epimakhova EV, Simutkin GG, Bokhan NA, et al. Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders. Journal of Personalized Medicine. 2023;13(9):1423. doi:10.3390/jpm13091423
BibTeX
@article{Levchuk2023,
author = {Levchuk, Lyudmila A and Roschina, Olga V and Mikhalitskaya, Ekaterina V and Epimakhova, Elena V and Simutkin, German G and Bokhan, Nikolay A and Ivanova, Svetlana A},
title = {Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {9},
pages = {1423},
doi = {10.3390/jpm13091423}
}
EUVIMED